MORF实时信号 | 通过Getagraph.com最大化利润

出售 108423 min ago

@ $37.26

发出时间: 15 Feb 2024 @ 04:46

回报率: -24.93%

上一信号: Feb 15 - 03:06

上一信号: 购买

回报率: 0.38 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 04:00):

Stats
今日成交量	341 998
平均成交量	498 550
市值	1.40B
EPS	$0 ( 2024-04-23 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.77
ATR14	$0.0490 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rogers Bruce	Buy	7 400	Common Stock
2024-03-27	Rogers Bruce	Sell	7 400	Stock Option (right to buy Common Stock)
2024-03-18	Cooper Simon Peter	Buy	170 000	Employee Stock Options (right to buy)
2024-03-18	Cooper Simon Peter	Buy	14 000	Restricted Stock Unit
2024-03-18	Cooper Simon Peter	Buy	7 000	Restricted Stock Unit

INSIDER POWER
69.64
Last 99 transactions
Buy: 2 671 692 \| Sell: 511 174

音量相关性

長: -0.12 (neutral)

短: 0.87 (strong)

Signal:(54.103) Same movement expected

Morphic Holding Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Morphic Holding Inc 相关性 - 货币/商品

0.51
( weak )

0.55
( weak )

0.00
( neutral )

0.10
( neutral )

0.00
( neutral )

-0.70
( moderate negative )

Morphic Holding Inc 财务报表

Annual	2023
营收:	$521 000
毛利润:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2023
营收:	$521 000
毛利润:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2022
营收:	$70.81M
毛利润:	$69.80M (98.58 %)
EPS:	$-1.550

FY	2021
营收:	$19.79M
毛利润:	$19.79M (100.00 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.